CYCART
DEAD

Serial Number

90765924

Owner

CELULARITY, INC.

Attorney

Camille M. Miller

First Use Date

Jan 7, 2020

Filing Date

Jun 10, 2021

Add to watchlist:

No watchlists yet
View on USPTO

CYCART Trademark

Serial Number: 90765924

CYCART is a trademark filed by CELULARITY, INC. on June 10, 2021. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals). The application is currently no longer active.

Owner Contact Info

CELULARITY, INC. (50 trademarks)

33 TECHNOLOGY DRIVE
WARREN, NJ 07059

Entity Type: 03

Trademark Details

Filing Date

June 10, 2021

Registration Date

Not Registered

First Use Anywhere

January 7, 2020

First Use in Commerce

June 2, 2021

Goods & Services

Cells and biological preparations intended for medical and clinical use, namely, blood, stem cells, placental-derived cells, umbilical cord cells, placental-derived T cells, chimeric antigen receptor (CAR) T cells, umbilical cord blood, and placental allograft tissue; bioengineered cells for use in immunotherapies for cancer and other diseases; human allograft tissue made from human umbilical cords and human placentas intended for subsequent implantation; human amniotic membrane and human chorionic membrane intended for subsequent implantation; human collagen compositions and extracellular matrix compositions intended for subsequent implantation; biological products for medical use, namely, placental-derived natural killer cells, and placental-derived cytotoxic T cells with a chimeric antigen receptor (CAR) specific for a cancer or other disease-associated antigen; biological tissue intended for use as a wound covering and burn dressing; wound dressings; burn dressings; surgical dressings; pharmaceutical preparations for wounds and burns; and written instructional materials distributed in connection with the aforesaid goods; biological products for medical use, namely, placental-derived cytotoxic T cells with a chimeric antigen receptor (CAR) specific for a cancer or other disease-associated antigen

Bioengineered cells for use in scientific, laboratory and medical research; human allograft tissue made from human umbilical cords and human placentas for use in scientific, laboratory and medical research; placental-derived cells, chimeric antigen receptor (CAR) T cells, and placental-derived T cells with a chimeric antigen receptor (CAR), all for use in scientific, laboratory and medical research

Filing History

EXPARTE APPEAL TERMINATED
Aug 18, 2023 EXPT
EXPARTE APPEAL DISMISSED AS MOOT
Aug 18, 2023 EXDM
ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND
Jun 15, 2023 MAB2
ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND
Jun 15, 2023 MAB2
ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
Jun 15, 2023 ABN2
ASSIGNED TO EXAMINER
May 31, 2023 DOCK
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Feb 14, 2023 GNRN
NON-FINAL ACTION E-MAILED
Feb 14, 2023 GNRT
NON-FINAL ACTION WRITTEN
Feb 14, 2023 CNRT
TEAS REQUEST FOR RECONSIDERATION RECEIVED
Dec 16, 2022 ERFR
EX PARTE APPEAL-INSTITUTED
Dec 16, 2022 EXPI
JURISDICTION RESTORED TO EXAMINING ATTORNEY
Dec 16, 2022 JURT
EXPARTE APPEAL RECEIVED AT TTAB
Dec 16, 2022 EXAF
NOTIFICATION OF FINAL REFUSAL EMAILED
Jun 16, 2022 GNFN
FINAL REFUSAL E-MAILED
Jun 16, 2022 GNFR
FINAL REFUSAL WRITTEN
Jun 16, 2022 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
Apr 13, 2022 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Apr 12, 2022 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Apr 12, 2022 TROA
NOTICE OF ACCEPTANCE OF AMENDMENT TO ALLEGE USE E-MAILED
Mar 9, 2022 AAUA
USE AMENDMENT ACCEPTED
Mar 8, 2022 IUAA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Mar 8, 2022 GNRN
NON-FINAL ACTION E-MAILED
Mar 8, 2022 GNRT
NON-FINAL ACTION WRITTEN
Mar 8, 2022 CNRT
ASSIGNED TO EXAMINER
Mar 1, 2022 DOCK
AMENDMENT TO USE PROCESSING COMPLETE
Sep 2, 2021 AUPC
USE AMENDMENT FILED
Sep 2, 2021 IUAF
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Aug 30, 2021 NWOS
TEAS AMENDMENT OF USE RECEIVED
Jun 15, 2021 EAAU
NEW APPLICATION ENTERED
Jun 14, 2021 NWAP